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Background: Adding a second antiplatelet agent to aspirin is more effective than aspirin alone in preventing repeat vascular events in acute 
coronary syndrome (ACS) patients. We sought to determine the cost effectiveness of universal or genotype driven use of dual antiplatelet strategies 
in ACS.
Methods: A hybrid decision tree/Markov model was used to calculate lifetime costs, quality adjusted life years (QALYs) and incremental cost 
effectiveness ratios (ICERs) of 1 year of universal (given to all patients) or genotype driven (given only to patients with a CYP2C19 reduced function 
allele, others received clopidogrel) ticagrelor or prasugrel compared to universal clopidogrel. We assumed a cohort of 65 year old ACS patients. The 
analysis was conducted from the Medicare perspective and used a 1 year cycle length. Data depicting the efficacy and safety of dual antiplatelet 
strategies were taken from multinational randomized trials.
Results: Costs and QALYs for each dual antiplatelet strategy are provided in the Table. Compared to universal clopidogrel, universal ticagrelor 
was the most cost effective alternative (ICER=$4,057/QALY), followed by genotype driven ticagrelor (ICER=$5,128/QALY), universal prasugrel 
(ICER=$11,153/QALY) and genotype driven prasugrel (ICER=$13,947/QALY). 
Conclusions: All evaluated alternatives to universal clopidogrel are likely cost effective in ACS patients. Forgoing genotyping and prescribing 
ticagrelor to all patients may be the most cost-effective strategy.
Table. Lifetime costs and quality adjusted life years for each available dual antiplatelet strategy
Strategy Lifetime Costs in 2011 US$ QALYs
Universal 
Clopidogrel $48,949 7.906
Ticagrelor $49,521 8.047
Prasugrel $49,752 7.978
Genotype driven 
Ticagrelor $49,149 7.945
Prasugrel $49,214 7.925
